173 related articles for article (PubMed ID: 26914658)
1. The Cost Effectiveness of Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the USA.
Ágh T; Pawaskar M; Nagy B; Lachaine J; Vokó Z
Clin Drug Investig; 2016 Apr; 36(4):305-12. PubMed ID: 26914658
[TBL] [Abstract][Full Text] [Related]
2. Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2015 Apr; 69(4):410-21. PubMed ID: 25752762
[TBL] [Abstract][Full Text] [Related]
3. Time course of the effects of lisdexamfetamine dimesylate in two phase 3, randomized, double-blind, placebo-controlled trials in adults with binge-eating disorder.
McElroy SL; Hudson JI; Gasior M; Herman BK; Radewonuk J; Wilfley D; Busner J
Int J Eat Disord; 2017 Aug; 50(8):884-892. PubMed ID: 28481434
[TBL] [Abstract][Full Text] [Related]
4. Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials.
McElroy SL; Hudson J; Ferreira-Cornwell MC; Radewonuk J; Whitaker T; Gasior M
Neuropsychopharmacology; 2016 Apr; 41(5):1251-60. PubMed ID: 26346638
[TBL] [Abstract][Full Text] [Related]
5. Clinical Characteristics and Treatment Response to Lisdexamfetamine Dimesylate Versus Placebo in Adults With Binge Eating Disorder: Analysis by Gender and Age.
Kornstein SG; Bliss C; Kando J; Madhoo M
J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30817099
[TBL] [Abstract][Full Text] [Related]
6. A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.
Zimovetz EA; Joseph A; Ayyagari R; Mauskopf JA
Eur J Health Econ; 2018 Jan; 19(1):21-35. PubMed ID: 28093662
[TBL] [Abstract][Full Text] [Related]
7. Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial.
Guerdjikova AI; Mori N; Blom TJ; Keck PE; Williams SL; Welge JA; McElroy SL
Hum Psychopharmacol; 2016 Sep; 31(5):382-91. PubMed ID: 27650406
[TBL] [Abstract][Full Text] [Related]
8. Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive-Compulsive and Impulsive Features in Adults with Binge Eating Disorder.
McElroy SL; Mitchell JE; Wilfley D; Gasior M; Ferreira-Cornwell MC; McKay M; Wang J; Whitaker T; Hudson JI
Eur Eat Disord Rev; 2016 May; 24(3):223-31. PubMed ID: 26621156
[TBL] [Abstract][Full Text] [Related]
9. A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate.
Zimovetz EA; Beard SM; Hodgkins P; Bischof M; Mauskopf JA; Setyawan J
CNS Drugs; 2016 Oct; 30(10):985-96. PubMed ID: 27530525
[TBL] [Abstract][Full Text] [Related]
10. Lisdexamfetamine in Pediatric Binge Eating Disorder: A Retrospective Chart Review.
Guerdjikova AI; Blom TJ; Mori N; Matthews A; Cummings T; Casuto LL; McElroy SL
Clin Neuropharmacol; 2019; 42(6):214-216. PubMed ID: 31725476
[TBL] [Abstract][Full Text] [Related]
11. LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence.
Ezard N; Dunlop A; Hall M; Ali R; McKetin R; Bruno R; Phung N; Carr A; White J; Clifford B; Liu Z; Shanahan M; Dolan K; Baker AL; Lintzeris N
BMJ Open; 2018 Jul; 8(7):e020723. PubMed ID: 30030312
[TBL] [Abstract][Full Text] [Related]
12. Lisdexamfetamine and binge-eating disorder: A systematic review and meta-analysis of the preclinical and clinical data with a focus on mechanism of drug action in treating the disorder.
Schneider E; Higgs S; Dourish CT
Eur Neuropsychopharmacol; 2021 Dec; 53():49-78. PubMed ID: 34461386
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial.
Hudson JI; McElroy SL; Ferreira-Cornwell MC; Radewonuk J; Gasior M
JAMA Psychiatry; 2017 Sep; 74(9):903-910. PubMed ID: 28700805
[TBL] [Abstract][Full Text] [Related]
14. Exploring bi-directional impacts of Lisdexamfetamine dimesylate on psychological comorbidities and quality of life in people with Binge Eating Disorder.
Griffiths KR; Boulet S; Barakat S; Touyz S; Hay P; Maguire S; Kohn MR
J Eat Disord; 2024 Jun; 12(1):80. PubMed ID: 38872181
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapeutic strategies for treating binge eating disorder. Evidence from clinical trials and implications for clinical practice.
Amodeo G; Cuomo A; Bolognesi S; Goracci A; Trusso MA; Piccinni A; Neal SM; Baldini I; Federico E; Taddeucci C; Fagiolini A
Expert Opin Pharmacother; 2019 Apr; 20(6):679-690. PubMed ID: 30696303
[TBL] [Abstract][Full Text] [Related]
16. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
Lachaine J; Sikirica V; Mathurin K
BMC Psychiatry; 2016 Jan; 16():11. PubMed ID: 26774811
[TBL] [Abstract][Full Text] [Related]
17. Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder.
Ward K; Citrome L
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):229-238. PubMed ID: 29258368
[TBL] [Abstract][Full Text] [Related]
18. Effect of lisdexamfetamine on emotional network brain dysfunction in binge eating disorder.
Fleck DE; Eliassen JC; Guerdjikova AI; Mori N; Williams S; Blom TJ; Beckwith T; Tallman MJ; Adler CM; DelBello MP; Strakowski SM; McElroy SL
Psychiatry Res Neuroimaging; 2019 Apr; 286():53-59. PubMed ID: 30903953
[TBL] [Abstract][Full Text] [Related]
19. Evaluating functional disability in clinical trials of lisdexamfetamine dimesylate in binge eating disorder using the Sheehan Disability Scale.
Yee KS; Pokrzywinski R; Hareendran A; Shaffer S; Sheehan DV
Int J Methods Psychiatr Res; 2021 Mar; 30(1):e1849. PubMed ID: 32841462
[TBL] [Abstract][Full Text] [Related]
20. A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder.
Gasior M; Hudson J; Quintero J; Ferreira-Cornwell MC; Radewonuk J; McElroy SL
J Clin Psychopharmacol; 2017 Jun; 37(3):315-322. PubMed ID: 28383364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
